Pharma

Jan 7 2018

Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #international #pharma #jobs

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …

Jan 7 2018

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #pharmaceutical #formulation #companies

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

Dec 24 2017

Sun joins dermatology rush with $230M DUSA buyout #mitsubishi #tanabe #pharma

#dusa pharma # Sun joins dermatology rush with $230M DUSA buyout Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics. Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne. “DUSA …

Dec 24 2017

Sun Pharma to buy Dusa for $230 million #pharma #training

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …

Dec 8 2017

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #medical #sales #jobs

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

Dec 8 2017

DUSA – News and Analysis – DUSA Pharmaceuticals, Inc #jobs #in #pharmaceutical #industry

#dusa pharma # DUSA is a vertically integrated dermatology company that is developing and marketing Levulan PDT and other products for common skin conditions. We operate in two segments, Photodynamic Therapy, or PDT, Drug and Device Products and Non-Photodynamic Therapy, or Non-PDT, Drug Products. Our Levulan® Kerastick® and BLU-U® products comprise our PDT segment, while Nicomide®, ClindaReach® and the other products acquired in the acquisition of Sirius comprise our Non-PDT segment. Our currently marketed products include among others Levulan® Kerastick® 20% Topical Solution with photodynamic therapy, the BLU-U® brand light source, and certain products acquired in the March 10, 2006 …

Nov 29 2017

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #pharmacia

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

Nov 22 2017

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #pharmaceutical #manufacturer

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

Nov 13 2017

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #astellas #pharma #europe

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

Sep 30 2017

Sun Pharma to buy Dusa for $230 million #jobs #in #pharmaceuticals

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …

Sep 5 2017

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #pharmaceutical #company #news

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

Aug 25 2017

Sun joins dermatology rush with $230M DUSA buyout #cerulean #pharma

#dusa pharma # Sun joins dermatology rush with $230M DUSA buyout Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics. Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne. “DUSA …

Aug 25 2017

DUSA – News and Analysis – DUSA Pharmaceuticals, Inc #pharma #compliance

#dusa pharma # DUSA is a vertically integrated dermatology company that is developing and marketing Levulan PDT and other products for common skin conditions. We operate in two segments, Photodynamic Therapy, or PDT, Drug and Device Products and Non-Photodynamic Therapy, or Non-PDT, Drug Products. Our Levulan® Kerastick® and BLU-U® products comprise our PDT segment, while Nicomide®, ClindaReach® and the other products acquired in the acquisition of Sirius comprise our Non-PDT segment. Our currently marketed products include among others Levulan® Kerastick® 20% Topical Solution with photodynamic therapy, the BLU-U® brand light source, and certain products acquired in the March 10, 2006 …

Aug 14 2017

DUSA – News and Analysis – DUSA Pharmaceuticals, Inc #pharma #conference #2013

#dusa pharma # DUSA is a vertically integrated dermatology company that is developing and marketing Levulan PDT and other products for common skin conditions. We operate in two segments, Photodynamic Therapy, or PDT, Drug and Device Products and Non-Photodynamic Therapy, or Non-PDT, Drug Products. Our Levulan® Kerastick® and BLU-U® products comprise our PDT segment, while Nicomide®, ClindaReach® and the other products acquired in the acquisition of Sirius comprise our Non-PDT segment. Our currently marketed products include among others Levulan® Kerastick® 20% Topical Solution with photodynamic therapy, the BLU-U® brand light source, and certain products acquired in the March 10, 2006 …

Aug 14 2017

India s Sun to acquire Dusa Pharma #pharma #pipeline

#dusa pharma # India’s Sun to acquire Dusa Pharma Sun Pharmaceutical Industries of India is shelling out around $230 million to buy US dermatology specialist Dusa Pharmaceuticals. Specifically, the Mumbai-based company is paying $8.00 per share in cash, a 38% premium to Dusa’s closing price on November 7. It is getting access to the latter’s Levulan (aminolevulinic acid), a combination therapy is approved by the US Food and Drug Administration for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The firm also markets Blu-U, for moderate inflammatory acne vulgaris and general dermatological conditions. Sun managing director Dilip …

Aug 7 2017

DUSA – News and Analysis – DUSA Pharmaceuticals, Inc #list #pharmaceutical #companies

#dusa pharma # DUSA is a vertically integrated dermatology company that is developing and marketing Levulan PDT and other products for common skin conditions. We operate in two segments, Photodynamic Therapy, or PDT, Drug and Device Products and Non-Photodynamic Therapy, or Non-PDT, Drug Products. Our Levulan® Kerastick® and BLU-U® products comprise our PDT segment, while Nicomide®, ClindaReach® and the other products acquired in the acquisition of Sirius comprise our Non-PDT segment. Our currently marketed products include among others Levulan® Kerastick® 20% Topical Solution with photodynamic therapy, the BLU-U® brand light source, and certain products acquired in the March 10, 2006 …

Aug 7 2017

Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #pharma #advertising

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …

Jul 31 2017

Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #pharma #medical

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …

Jul 22 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #pharma #manufacturer

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Jul 22 2017

Sun Pharma to buy Dusa for $230 million #largest #pharmaceutical #companies

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …

Jul 8 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #diamond #pharma

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Jul 8 2017

Sun joins dermatology rush with $230M DUSA buyout #pharma #regulatory

#dusa pharma # Sun joins dermatology rush with $230M DUSA buyout Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics. Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne. “DUSA …

Jun 25 2017

Sun Pharma to buy Dusa for $230 million #pharmaceutical #marketing

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …

Jun 25 2017

Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #leading #pharmaceutical #companies #2013

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …

Jun 13 2017

Sun Pharma to buy Dusa for $230 million #top #20 #pharma

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …

Jun 12 2017

Sun joins dermatology rush with $230M DUSA buyout #global #pharmaceutical #industry

#dusa pharma # Sun joins dermatology rush with $230M DUSA buyout Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics. Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne. “DUSA …

Jun 12 2017

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #laureate #pharma

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

May 28 2017

Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #generic #pharmaceutical

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …

May 28 2017

Sun joins dermatology rush with $230M DUSA buyout #pharmaceutical #marketing #jobs

#dusa pharma # Sun joins dermatology rush with $230M DUSA buyout Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics. Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne. “DUSA …

May 13 2017

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #pharma #science

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

May 13 2017

Sun Pharma to buy Dusa for $230 million #naveh #pharma

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …

May 13 2017

Sun joins dermatology rush with $230M DUSA buyout #pharma #supply #chain

#dusa pharma # Sun joins dermatology rush with $230M DUSA buyout Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics. Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne. “DUSA …

May 13 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #astellas #pharma #inc

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Apr 27 2017

Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #generic #drug #industry

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …

Apr 27 2017

Sun joins dermatology rush with $230M DUSA buyout #astellas #pharma

#dusa pharma # Sun joins dermatology rush with $230M DUSA buyout Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics. Now, India-based Sun Pharmaceutical is joining the party. It’s buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday’s closing price. The key prizes: DUSA’s Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne. “DUSA …

Apr 18 2017

Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #fulcrum #pharma

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …

Apr 9 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #drug #manufacturer

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Apr 9 2017

Sun Pharma inks pact to buy DUSA for $230 million – The Hindu #pharma #logo

#dusa pharma # Sun Pharma inks pact to buy DUSA for $230 million Sun Pharmaceutical Industries, on Thursday, said it had inked a pact to acquire U.S.-based DUSA Pharmaceuticals for around $230 million (about Rs.1,250 crore). Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a statement. Under the terms of the agreement, a 100 per cent subsidiary of Sun Pharma will commence a tender offer for all of the outstanding common stock of …

Apr 8 2017

DUSA – News and Analysis – DUSA Pharmaceuticals, Inc #catalent #pharma #solutions

#dusa pharma # DUSA is a vertically integrated dermatology company that is developing and marketing Levulan PDT and other products for common skin conditions. We operate in two segments, Photodynamic Therapy, or PDT, Drug and Device Products and Non-Photodynamic Therapy, or Non-PDT, Drug Products. Our Levulan® Kerastick® and BLU-U® products comprise our PDT segment, while Nicomide®, ClindaReach® and the other products acquired in the acquisition of Sirius comprise our Non-PDT segment. Our currently marketed products include among others Levulan® Kerastick® 20% Topical Solution with photodynamic therapy, the BLU-U® brand light source, and certain products acquired in the March 10, 2006 …

Mar 30 2017

DUSA – News and Analysis – DUSA Pharmaceuticals, Inc #pharma #index

#dusa pharma # DUSA is a vertically integrated dermatology company that is developing and marketing Levulan PDT and other products for common skin conditions. We operate in two segments, Photodynamic Therapy, or PDT, Drug and Device Products and Non-Photodynamic Therapy, or Non-PDT, Drug Products. Our Levulan® Kerastick® and BLU-U® products comprise our PDT segment, while Nicomide®, ClindaReach® and the other products acquired in the acquisition of Sirius comprise our Non-PDT segment. Our currently marketed products include among others Levulan® Kerastick® 20% Topical Solution with photodynamic therapy, the BLU-U® brand light source, and certain products acquired in the March 10, 2006 …

Mar 30 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #biopharma

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Mar 29 2017

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #new #pharmaceuticals

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

Mar 15 2017

Sun Pharma to acquire US dermatology company DUSA Pharma #pharma #industries

#dusa pharma # Sun Pharma to acquire US dermatology company DUSA Pharma (Under the terms of the agreement, ) AHMEDABAD: Mumbai-based Sun Pharmaceutical Industries Ltd is set to acquire US-based DUSA Pharmaceuticals, Inc, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform. The two companies entered into a definitive agreement. Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries Ltd will commence a tender offer for all of the outstanding common stock of DUSA at a price of $8.00 per share in cash, a 38% premium to the closing …

Mar 15 2017

India s Sun to acquire Dusa Pharma #pharma #consultants

#dusa pharma # India’s Sun to acquire Dusa Pharma Sun Pharmaceutical Industries of India is shelling out around $230 million to buy US dermatology specialist Dusa Pharmaceuticals. Specifically, the Mumbai-based company is paying $8.00 per share in cash, a 38% premium to Dusa’s closing price on November 7. It is getting access to the latter’s Levulan (aminolevulinic acid), a combination therapy is approved by the US Food and Drug Administration for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The firm also markets Blu-U, for moderate inflammatory acne vulgaris and general dermatological conditions. Sun managing director Dilip …

Feb 11 2017

India s Sun to acquire Dusa Pharma #map #pharma

#dusa pharma # India’s Sun to acquire Dusa Pharma Sun Pharmaceutical Industries of India is shelling out around $230 million to buy US dermatology specialist Dusa Pharmaceuticals. Specifically, the Mumbai-based company is paying $8.00 per share in cash, a 38% premium to Dusa’s closing price on November 7. It is getting access to the latter’s Levulan (aminolevulinic acid), a combination therapy is approved by the US Food and Drug Administration for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The firm also markets Blu-U, for moderate inflammatory acne vulgaris and general dermatological conditions. Sun managing director Dilip …

Feb 11 2017

DUSA – News and Analysis – DUSA Pharmaceuticals, Inc #m #pharma

#dusa pharma # DUSA is a vertically integrated dermatology company that is developing and marketing Levulan PDT and other products for common skin conditions. We operate in two segments, Photodynamic Therapy, or PDT, Drug and Device Products and Non-Photodynamic Therapy, or Non-PDT, Drug Products. Our Levulan® Kerastick® and BLU-U® products comprise our PDT segment, while Nicomide®, ClindaReach® and the other products acquired in the acquisition of Sirius comprise our Non-PDT segment. Our currently marketed products include among others Levulan® Kerastick® 20% Topical Solution with photodynamic therapy, the BLU-U® brand light source, and certain products acquired in the March 10, 2006 …

Jan 25 2017

India s Sun to acquire Dusa Pharma #big #pharma #etf

#dusa pharma # India’s Sun to acquire Dusa Pharma Sun Pharmaceutical Industries of India is shelling out around $230 million to buy US dermatology specialist Dusa Pharmaceuticals. Specifically, the Mumbai-based company is paying $8.00 per share in cash, a 38% premium to Dusa’s closing price on November 7. It is getting access to the latter’s Levulan (aminolevulinic acid), a combination therapy is approved by the US Food and Drug Administration for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The firm also markets Blu-U, for moderate inflammatory acne vulgaris and general dermatological conditions. Sun managing director Dilip …

Jan 23 2017

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #pharma #logos

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

Dec 7 2016

Dusa Pharma: Latest News – Videos, Photos about Dusa Pharma #pure #pharma

#dusa pharma # DUSA PHARMA Pharma headwinds here to stay, tread with caution Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook’s healthy. 1 Sep, 2016, 08.22AM IST IT, pharma ultimately going to perform: Rakesh Jhunjhunwala In IT and pharma, the first few names remain the same, but the order keeps changi. 30 Aug, 2016, 12.25PM IST Pharma companies in race to acquire Zincovit, Zincofer Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three. 29 Aug, 2016, 05.13PM IST Buy Escorts and Sun Pharma: Experts As …

Dec 7 2016

India s Sun to acquire Dusa Pharma #ajanta #pharma #products

#dusa pharma # India’s Sun to acquire Dusa Pharma Sun Pharmaceutical Industries of India is shelling out around $230 million to buy US dermatology specialist Dusa Pharmaceuticals. Specifically, the Mumbai-based company is paying $8.00 per share in cash, a 38% premium to Dusa’s closing price on November 7. It is getting access to the latter’s Levulan (aminolevulinic acid), a combination therapy is approved by the US Food and Drug Administration for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The firm also markets Blu-U, for moderate inflammatory acne vulgaris and general dermatological conditions. Sun managing director Dilip …